Effect of c-mpl ligands after total body irradiation, (TBI) with and without allogeneic hematopoietic stem cell transplantation: Low-dose TBI does not prevent sensitization

Biology of Blood and Marrow Transplantation

Volumn 8, Issue 7, 2002, Pages 360-367

  Nash, Richard A ^a   Takatu, Alessandra ^a   Feng, Ziding ^a   Slichter, Sherrill ^a   Abrams, Kraig ^a   Espino, German ^a   Gass, M John ^a   Georges, George E ^a   McSweeney, Peter A ^a   Shulman, Howard M ^a   Storb, Rainer ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Antibodies; c mpl ligand; Dogs; PEG rhMGDF; Platelet recovery; rhTPO; Sensitization; Thrombopoietin; Total body irradiation

Indexed keywords

NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CELL COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG SENSITIZATION; GRANULOCYTE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; NEUTROPHIL; NONHUMAN; RADIATION DOSE; THROMBOCYTE COUNT; TIME; WHOLE BODY RADIATION;

EID: 0036053616     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2002.v8.pm12171482     Document Type: Article

References (51)

1. Secondary failure of platelet recovery after hematopoietic stem cell transplantation
2. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation
3. The problem of thrombocytopenia after hematopoietic stem cell transplantation
4. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia
5. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia
6. Radiotherapy-associated neutropenia and thrombocytopenia: Analysis of risk factors and development of a predictive model
7. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice
8. A single dose of thrombopoietin shortly after myelosuppressive total body irradiation prevents pancytopenia in mice by promoting short-term multilineage spleen-repopulating cells at the transient expense of bone cells
9. Effects of rhIL-11 on normal dogs and after sublethal radiation
10. Thrombopoietin promotes hematopoietic recovery and survival after high-dose whole body irradiation
11. Thrombopoietin and the hematopoietic stem cell
12. Normal platelets and megakaryocytes are produced in vivo in the absence of thrombopoietin
13. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia
14. A single injection of pegylated murine megakaryocyte growth and development factor (MGDF) into mice is sufficient to produce a profound stimulation of megakaryocyte frequency, size, and ploidization
15. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates
16. Thrombopoietin, but not erythropoietin, directly stimulates multilineage growth of primitive murine bone marrow progenitor cells in synergy with early acting cytokines: Distinct interactions with the ligands for c-kit and FLT3
17. Thrombopoietin stimulates colony-forming unit-megakaryocyte proliferation and megakaryocyte maturation independently of cytokines that signal through the gp130 receptor subunit
18. Ultrastructure of platelet formation by human megakaryocytes cultured with the Mpl ligand
19. Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia
20. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and recovery following high-dose chemotherapy
21. Megakaryocyte growth and d development factor ameliorates carboplatin-induced thrombocytopenia in mice
22. Marrow toxicity of fractionated versus single dose total body irradiation is identical in a canine model
23. Chronic thrombocytopenia is induced in dogs by development of cross-reacting antibodies to the MpL ligand
24. Identification and characterization of a highly polymorphic microsatellite marker within the canine MHC class I region
25. Histocompatibility testing of dog families with highly polymorphic microsatellite markers
26. Molecular analysis of DLA-DRBB1 polymorphism
27. Thrombocytopenia in dogs induced by granulocyte-macrophage colony-stimulating factor: Increased destruction of circulating platelets
28. Theoretical Statistics
29. An Introduction to the Bootstrap
30. Nonparametric Statistics for the Behavioral Sciences
31. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after aplasia
32. Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy
33. Prevention of thrombocytopenia by thrombopoietin in myelosuppressed rhesus monkeys accompanied by prominent erythropoietic stimulation and iron depletion
34. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and bone marrow cells
35. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer
36. Enhancement of platelet-frecovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer
37. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia
38. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia
39. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients
40. Megakaryocyte growth and development factor stimulates enhanced platelet recovery in mice after bone marrow transplantation
41. Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice
42. Lack of efficacy of thrombopoietin and granulocyte-macrophage colony-stimulating factor after total body irradiation and autologous bone marrow transplantation in Rhesus monkeys
43. The efficacy of recombinant thrombopoietin in murine and nonhuman primate models for radiation-induced myelosuppression and stem cell transplantation
44. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation
45. Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: A phase I pharmacokinetic and pharmacodynamic study
46. Use of PEG-rHuMGDF in platelet engraftment after autologous stem cell transplantation
47. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation
48. Thrombopoietin (TPO) knockout phenotype induced by cross-reactive antibodies against TPO following injection of mice with recombinant adenovirus encoding human TPO
49. Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia
50. The appearance of antithrombopoietin antibody and circulating thrombopoietin-IgG complexes in a patient developing thrombocytopenia after the injection of PEG-rHuMGDF
51. A randomized, placebo-controlled, blinded, dose scheduling trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-RHUMGDF) with filgrastim support in non-small cell lung cancer with paclitaxel and carboplatin during multiple cycles of chemotherapy